Retinitis Pigmentosa (RP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
Retinitis
Pigmentosa (RP) Market Outlook
Thelansis’s “Retinitis Pigmentosa
(RP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2026 To 2036” covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Retinitis
Pigmentosa (RP) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Retinitis
Pigmentosa (RP) Overview
Retinitis pigmentosa (RP) is a group
of inherited retinal dystrophies marked by progressive photoreceptor
degeneration, driven by mutations across more than 80 genes (including RHO,
USH2A, and RPGR). It exhibits a peripheral-to-central degeneration pattern
where rod dysfunction typically precedes cone involvement. Patients present
with early night blindness, progressive visual field constriction producing
tunnel vision, and late-stage central blindness. Diagnosis integrates
fundoscopic examination revealing characteristic bone-spicule deposits,
electroretinography showing blunted responses, and genetic testing to confirm
variants. The AAV-based gene therapy voretigene neparvovec represents a
landmark precision standard specifically for biallelic RPE65 mutations. For the
vast non-RPE65 population, vitamin A palmitate provides modest, heavily debated
slowing. In 2026, the advanced therapeutic paradigm has shifted toward
gene-agnostic restoration. This is led by the optogenetic gene therapy MCO-010
(sonpiretigen isteparvovec), which uses an AAV2 vector to express
multi-characteristic opsins in retinal bipolar cells. In early 2026, its
rolling BLA was completed following three-year REMAIN trial extension data
showing durable, significant visual acuity gains. Low vision aids complete the
modern management model.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by robust research, including:
- In-depth interviews with leading KOLs
and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based
automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets
and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the most
promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment